News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyprotex (COTXF.PK): US Business Development Executive Appointment



4/15/2010 10:41:09 AM

MACCLESFIELD, UK--(Marketwire - April 15, 2010) -


Thursday 15 April 2010 Cyprotex PLC ("Cyprotex" or the "Company" or the "Group") Appointment of Executive Director, Business Development - North America Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, announces the appointment of Ben Butterfield as Executive Director for Business Development in North America. Cyprotex enables its customers to access secure, high quality Absorption, Distribution, Metabolism, Excretion / Toxicity (ADMET) data without incurring significant overheads. Its highly automated platform guarantees high throughput, reproducibility and rapid turnaround of ADMET data, setting new industry standards for this sector of the market. As previously stated, Cyprotex has been restructuring its USA and Rest of World sales activities as the Company believes that further investment in the right personnel will allow the Company to establish its position in these markets and capitalise on the opportunity they present. Specifically, Ben's appointment will be a key development in exploiting the opportunity that exists in North America. Ben was previously Business Development Manager for Toxikon Corporation, which provides preclinical safety research to medical device and pharmaceutical companies. He was responsible for the North East of the US. Ben has a decade's experience of selling products and services to the healthcare / pharmaceutical industry including two years at Chantest Inc. where he promoted ADME studies to the preclinical sector. He has a psychology / premed degree from Loyola University in New Orleans and is trained in FDA preclinical compliance regulations. Ben's appointment is part of an ongoing process to strengthen Cyprotex's commercial team. Last year, Simon Bury was recruited as Chief Commercial Officer. Simon has restructured the sales team to achieve greater effectiveness and has hired a mainland Europe based Business Development Manager to support European sales. Cyprotex has also further increased the role of its scientific Study Managers to strengthen the relationships with current key customers and this has been and will be central to its success in developing more 'strategic' customers. Tony Baxter, Chief Executive of Cyprotex, said:"I am delighted that Ben has joined Cyprotex. His experience should transform our efforts in North America where Cyprotex has historically been underrepresented. As the world's largest pharmaceutical market we believe that North America represents a significant opportunity and I am confident that we will make considerable inroads into the market." For further information: Cyprotex PLC Tel: +44 (0) 1625 505 100 Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer ir@cyprotex.com www.cyprotex.com Execution Noble & Company Tel: +44 (0) 20 7456 9191 John Llewellyn-Lloyd john.llewellyn-lloyd@execution-noble.com Sam Reynolds sam.reynolds@execution-noble.com www.execution-noble.com Financial Dynamics Tel: +44 (0) 20 7831 3113 Ben Brewerton / Ben Atwell / Mo Noonan cyprotex@fd.com www.fd.com This information is provided by RNS The company news service from the London Stock Exchange END


Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com


Read at BioSpace.com


comments powered by Disqus
Cyprotex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES